I don't think anybody is realy saying Warren would be interested in buying Cellestis with his small change but that the company meets many of the criteria that he suggests we look for when investing in a young company.
At a lecture tonight - leading Sth Aust Prof. of Rheumatology talking about TFN inhibitors and spoke for quite a while on the serious issue with latent TB. He knew all about Quantiferon Gold but said not being used much in Sth Aust at the moment, he doesent know why, but it should be.
The use of TFN inhibitors will increase significantly in the future as he expects significant price reductions and wider indications for use. All patients have to be tested for latent TB before use.
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
